iBio (NYSEMKT:IBIO) Trading Down 3.6%

iBio, Inc. (NYSEMKT:IBIO) fell 3.6% during mid-day trading on Wednesday . The company traded as low as $1.81 and last traded at $1.88. 269,653 shares were traded during mid-day trading, an increase of 138% from the average session volume of 113,212 shares. The stock had previously closed at $1.95.

iBio Price Performance

The firm has a 50 day simple moving average of $1.65. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91.

Hedge Funds Weigh In On iBio

Several institutional investors have recently bought and sold shares of IBIO. HighTower Advisors LLC bought a new position in iBio during the first quarter valued at $25,000. State Street Corp lifted its position in iBio by 55.7% during the first quarter. State Street Corp now owns 48,059 shares of the company’s stock valued at $100,000 after purchasing an additional 17,200 shares during the last quarter. US Bancorp DE lifted its position in iBio by 178.4% during the first quarter. US Bancorp DE now owns 67,100 shares of the company’s stock valued at $29,000 after purchasing an additional 43,000 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in iBio during the fourth quarter valued at $33,000. Finally, Bank of New York Mellon Corp bought a new position in iBio during the first quarter valued at $183,000. 7.90% of the stock is owned by hedge funds and other institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.